PRA Health Sciences, Inc. (NASDAQ:PRAH) had its target price hoisted by analysts at Credit Suisse Group from $80.00 to $84.00 in a research note issued to investors on Tuesday. The brokerage currently has an “outperform” rating on the medical research company’s stock. Credit Suisse Group’s target price would suggest a potential upside of 13.16% from the company’s previous close.

A number of other analysts also recently commented on PRAH. Robert W. Baird boosted their price objective on PRA Health Sciences from $82.00 to $83.00 and gave the stock an “outperform” rating in a research note on Tuesday. BidaskClub downgraded PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Bank of America Corporation began coverage on PRA Health Sciences in a research note on Monday, June 26th. They issued a “buy” rating and a $89.00 price objective on the stock. Jefferies Group LLC set a $73.00 price objective on PRA Health Sciences and gave the stock a “buy” rating in a research note on Thursday, June 1st. Finally, Citigroup Inc. reaffirmed a “buy” rating and set a $90.00 target price (up from $73.00) on shares of PRA Health Sciences in a research report on Wednesday, June 28th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. PRA Health Sciences presently has a consensus rating of “Buy” and an average price target of $75.25.

PRA Health Sciences (NASDAQ:PRAH) traded up 7.48% during mid-day trading on Tuesday, reaching $79.78. The company’s stock had a trading volume of 389,867 shares. The firm has a 50 day moving average price of $75.01 and a 200-day moving average price of $66.37. PRA Health Sciences has a 1-year low of $46.52 and a 1-year high of $80.99. The company has a market capitalization of $4.98 billion, a PE ratio of 47.66 and a beta of 0.45.

PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Monday, August 7th. The medical research company reported $0.62 earnings per share for the quarter, missing the consensus estimate of $0.72 by $0.10. PRA Health Sciences had a net margin of 5.85% and a return on equity of 21.87%. The business had revenue of $457.90 million for the quarter, compared to the consensus estimate of $447.79 million. During the same period in the previous year, the firm earned $0.63 EPS. The firm’s revenue was up .5% on a year-over-year basis. On average, equities analysts predict that PRA Health Sciences will post $3.15 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.dailypolitical.com/2017/08/08/pra-health-sciences-inc-prah-given-new-84-00-price-target-at-credit-suisse-group.html.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. First Bank & Trust increased its position in shares of PRA Health Sciences by 1.6% in the second quarter. First Bank & Trust now owns 3,211 shares of the medical research company’s stock worth $241,000 after buying an additional 52 shares in the last quarter. State Board of Administration of Florida Retirement System increased its position in shares of PRA Health Sciences by 0.6% in the first quarter. State Board of Administration of Florida Retirement System now owns 21,892 shares of the medical research company’s stock worth $1,428,000 after buying an additional 140 shares in the last quarter. Forward Management LLC increased its position in shares of PRA Health Sciences by 5.0% in the first quarter. Forward Management LLC now owns 4,762 shares of the medical research company’s stock worth $310,000 after buying an additional 226 shares in the last quarter. 1st Global Advisors Inc. increased its position in shares of PRA Health Sciences by 2.2% in the first quarter. 1st Global Advisors Inc. now owns 11,265 shares of the medical research company’s stock worth $735,000 after buying an additional 238 shares in the last quarter. Finally, Eqis Capital Management Inc. increased its position in shares of PRA Health Sciences by 6.5% in the second quarter. Eqis Capital Management Inc. now owns 4,217 shares of the medical research company’s stock worth $316,000 after buying an additional 259 shares in the last quarter.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.